EQRx, Inc. (EQRX) Stock

About EQRx, Inc.

EQRx, Inc. is a U.S.-based pharmaceutical firm dedicated to innovating therapies, predominantly for oncological (cancer) and immune-inflammatory conditions. The company's late-stage pipeline features two promising drug candidates in Phase III clinical trials: Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor specifically for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and Sugemalimab, an anti-programmed death-ligand 1 antibody aimed at treating Stage III and Stage IV NSCLC. Its broader developmental portfolio encompasses a range of additional clinical and pre-clinical assets. This portfolio includes Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor in Phase II trials for metastatic breast cancer; EQ176, an anti-programmed death-1 antibody undergoing Phase III development for primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor currently in various Phase I studies. Established in 2019, EQRx maintains its corporate headquarters in Cambridge, Massachusetts.

EQRx, Inc. is headquartered in US.

EQRx, Inc. (EQRX) stock trades at $2.34 with a market capitalization of $1.14B. The stock is valued at a price-to-earnings (P/E) ratio of 5.44, price-to-book of 0.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.58 and $4.75, and currently trades 50.7% below its 52-week high.

On profitability, EQRx, Inc. generates a return on equity (ROE) of 14.15%, above the typical market average, return on capital employed of -25.36%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.eqrx.com